2014
Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal Of Ocular Pharmacology And Therapeutics 2014, 30: 346-352. PMID: 24552305, DOI: 10.1089/jop.2013.0188.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansIntravitreal InjectionsMacular DegenerationMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityConceptsAge-related macular degenerationCentral macular thicknessAflibercept injectionsInitial visitMacular degenerationAnti-vascular endothelial growth factor treatmentNeovascular age-related macular degenerationEndothelial growth factor treatmentCentral macular edemaIntraocular pressure increaseSubset of patientsMain outcome measuresOptical coherence tomographyGrowth factor treatmentMacular thicknessNeovascular AgeOcular hypertensionSubmacular fluidVisual outcomeMacular edemaRetrospective studyVisual acuityOutcome measuresStudy populationPatients
2011
The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab
Lee ST, Adelman RA. The Treatment of Recurrent Central Serous Chorioretinopathy with Intravitreal Bevacizumab. Journal Of Ocular Pharmacology And Therapeutics 2011, 27: 611-614. PMID: 21810026, DOI: 10.1089/jop.2011.0045.Peer-Reviewed Original ResearchConceptsRecurrent central serous chorioretinopathyMean central macular thicknessCentral macular thicknessCentral serous chorioretinopathyPreinjection visual acuityVisual acuityOptical coherence tomographyIntravitreal bevacizumabSerous chorioretinopathyTreatment optionsLow-risk treatment optionYale Eye CenterIntravitreal bevacizumab injectionRetrospective case seriesEffective treatment optionLong-term efficacySub-retinal fluidNumber of injectionsFluorescein angiography imagingBevacizumab injectionRecurrent diseaseMacular thicknessMonth 3Month 6Case series